For the CML patients treated with imatinib (n = 96, GSE130404), Clu-CD34 and Clu-MPO gene expression signatures were able to predict early resistance to imatinib (Clu-CD34, AUC = 0.80, Clu-MPO, AUC = 0.82; Figure 4B–4D). This evidence concerns the gene MPO and chronic myelogenous leukemia, BCR-ABL1 positive.